March 24, 2022
RFA-HL-23-010 - Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
RFA-HL-23-011 - Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)
RFA-HL-23-012 - Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)
RFA-HL-23-013 - Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)
RFA-HL-23-014 - Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
NOT-HL-22-015 - Notice of Application Submission and Due Date Changes for RFA-HL-23-010, "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)"
NOT-HL-22-016- Notice of Application Due Date Changes for RFA-HL-23-011,"Catalyze:Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)"
NOT-HL-22-017- Notice of Application Due Date Changes for RFA-HL-23-012, "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)"
NOT-HL-22-018 - Application Due Date Changes for RFA-HL-23-013, "Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)"
National Heart, Lung, and Blood Institute (NHLBI)
The purpose of this Notice is to alert potential applicants to a change in key dates for RFA-HL-23-014, "Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)". Changes are shown in bold italics below.
Current dates:
| Application Due Dates | Review and Award Cycles | ||||
| New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| March 21, 2022 | March 21, 2022 | April 18, 2022 | July 1, 2022 | October 1, 2022 | December 1, 2022 |
| July 21, 2022 | July 21, 2022 | August 18, 2022 | November 1, 2022 | January 1, 2023 | April 1, 2023 |
| November 21, 2022 | November 21, 2022 | December 21, 2022 | March 1, 2023 | May 1, 2023 | July 1, 2023 |
| March 21, 2023 | March 21, 2023 | April 18, 2023 | July 1, 2023 | October 1, 2023 | December 1, 2023 |
| July 21, 2023 | July 21, 2023 | August 18, 2023 | November 1, 2023 | January 1, 2024 | April 1, 2024 |
| November 21, 2023 | November 21, 2023 | December 21, 2023 | March 1, 2024 | May 1, 2024 | July 1, 2024 |
| March 21, 2024 | March 21, 2024 | April 18, 2024 | July 1, 2024 | October 1, 2024 | December 1, 2024 |
| July 21, 2024 | July 21, 2024 | August 18, 2024 | November 1, 2024 | January 1, 2025 | April 1, 2025 |
| November 21, 2024 | November 21, 2024 | December 20, 2024 | March 1, 2025 | May 1, 2025 | July 1, 2025 |
Revised dates (in bold italics):
| Application Due Dates | Review and Award Cycles | ||||
| New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| March 21, 2022 | March 21, 2022 | April 18, 2022 | July 1, 2022 | October 1, 2022 | December 1, 2022 |
| July 21, 2022 | July 21, 2022 | August 18, 2022 | November 1, 2022 | January 1, 2023 | April 1, 2023 |
| November 21, 2022 | November 21, 2022 | December 21, 2022 | March 1, 2023 | May 1, 2023 | July 1, 2023 |
| February 21, 2023 | February 21, 2023 | April 18, 2023 | July 1, 2023 | October 1, 2023 | December 1, 2023 |
| July 21, 2023 | July 21, 2023 | August 18, 2023 | November 1, 2023 | January 1, 2024 | April 1, 2024 |
| November 21, 2023 | November 21, 2023 | December 21, 2023 | March 1, 2024 | May 1, 2024 | July 1, 2024 |
| February 21, 2024 | February 21, 2024 | April 18, 2024 | July 1, 2024 | October 1, 2024 | December 1, 2024 |
| July 22, 2024 | July 22, 2024 | August 19, 2024 | November 1, 2024 | January 1, 2025 | April 1, 2025 |
| November 21, 2024 | November 21, 2024 | December 20, 2024 | March 1, 2025 | May 1, 2025 | July 1, 2025 |
All other aspects of this FOA remain unchanged.
Mike Pieck, Ph.D.
Telephone: 301-827-7986
Email: [email protected]
and Human Services (HHS)
